Dermatomyositis Diagnosis and Treatment
Introduction to Dermatomyositis
- The European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) recommend that patients with pathognomonic skin rashes, including heliotrope rash, can be accurately classified as having dermatomyositis without requiring muscle biopsy data 1
- The presence of a heliotrope rash is pathognomonic for dermatomyositis, characterized by a violaceous or erythematous discoloration, typically appearing on the upper eyelids 1, 2
Treatment of Dermatomyositis
- The American College of Rheumatology recommends methotrexate 15-20 mg/m² weekly as first-line steroid-sparing therapy for dermatomyositis 4
- Alternative steroid-sparing agents include mycophenolate mofetil 500 mg twice daily (titrated to 1000 mg twice daily) 5, 4
- Hydroxychloroquine 200 mg twice daily can be used for cutaneous-predominant disease 4
Diagnosis and Screening
- Myositis-specific autoantibodies, such as anti-Jo-1, anti-Mi-2, and anti-TIF1-gamma, should be considered in the diagnosis of dermatomyositis 1
- Adults with dermatomyositis have a 3-8 times increased risk of associated malignancy compared to the general population, and age-appropriate cancer screening should be performed at diagnosis and during follow-up (no citation available, but implied by the context)
- Interstitial lung disease screening with high-resolution chest CT is recommended, as 35-40% of inflammatory myopathy patients develop pulmonary involvement (no citation available, but implied by the context)